Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog

Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog

Show other versions (1)

Bibliographic Details
Main Authors:	Yoshimi Niwano, Atsuo Iwasawa, Masahiko Ayaki
Format:	Article
Language:	English
Published:	SAGE Publishing 2014-02-01
Series:	Ophthalmology and Eye Diseases
Online Access:	http://www.la-press.com/ocular-surface-cytotoxicity-and-safety-evaluation-of-tafluprost-a-rece-article-a4063

Similar Items

Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog
by: Yoshimi Niwano, et al.
Published: (2014-01-01)

Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines
by: Masahiko Ayaki, et al.
Published: (2010-08-01)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
by: Ruangvaravate N, et al.
Published: (2020-10-01)

Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy
by: Kazuyoshi Kitamura, et al.
Published: (2018-01-01)

Comparative assessment of the cytotoxicity of six anti-inflammatory eyedrops in four cultured ocular surface cell lines, as determined by cell viability scores
by: Ayaki M, et al.
Published: (2012-11-01)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
by: Hommer A, et al.
Published: (2011-05-01)

Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
by: Dorota Pozarowska
Published: (2010-10-01)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
by: Lanzl I, et al.
Published: (2013-05-01)

Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
by: Clyde Schultz
Published: (2011-06-01)

Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
by: Clyde Schultz
Published: (2011-01-01)

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
by: Michael B Horsley, et al.
Published: (2009-03-01)

Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines
by: Masahiko Ayaki, et al.
Published: (2010-09-01)

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
by: Ermiş&nbsp;SS
Published: (2012-05-01)

Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
by: Makoto Aihara
Published: (2010-03-01)

Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis
by: Xi-Ting Yang, et al.
Published: (2020-03-01)

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
by: Wissam Georges El Hajj Moussa, et al.
Published: (2018-01-01)

The clinical effectiveness of tafluprost on Japanese normal-tension glaucoma patients
by: Nomura A, et al.
Published: (2018-03-01)

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review
by: Takagi Y, et al.
Published: (2018-09-01)

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
by: Inoue K, et al.
Published: (2013-07-01)

Impact of tafluprost and tafluprost/timolol on the thickness of the retina in the macular area
by: N. I. Kurysheva, et al.
Published: (2019-03-01)

Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects.
by: Shugyoku Ra, et al.
Published: (2017-01-01)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
by: Ikeda Y, et al.
Published: (2016-08-01)

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
by: Naoto Tokuda, et al.
Published: (2017-01-01)

Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs
by: Schmier JK, et al.
Published: (2014-06-01)

Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma
by: Hwang YH
Published: (2013-12-01)

Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
by: Masahiko Ayaki, et al.
Published: (2010-10-01)

A Prospective Study Evaluating IOP Changes after Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients
by: Stefano Ranno, et al.
Published: (2012-01-01)

Influence of BAK-Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open-Angle Glaucoma
by: Martina Tomić, et al.
Published: (2013-01-01)

Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension
by: Frenkel Ronald EP, et al.
Published: (2007-09-01)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
by: Sacchi M, et al.
Published: (2014-09-01)

Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
by: Liu Y, et al.
Published: (2012-12-01)

Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination
by: Natalia Ivanovna Kurysheva
Published: (2019-01-01)

Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma
by: Anton Hommer, et al.
Published: (2015-01-01)

Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye.
by: Naoko Aizawa, et al.
Published: (2017-01-01)

Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study
by: Teresa Rolle, et al.
Published: (2017-08-01)

Prostaglandins in glaucoma
by: Akram Rismanchian, et al.
Published: (2009-03-01)

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis
by: Oghenowede Eyawo, et al.
Published: (2009-07-01)

Lactones in the Synthesis of Prostaglandins and Prostaglandin Analogs
by: Constantin Tănase, et al.
Published: (2021-02-01)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
by: Nakamoto K, et al.
Published: (2018-02-01)

OCT angiography analysis of retinal vessel density in primary open-angle glaucoma with and without Tafluprost therapy
by: Hannah Weindler, et al.
Published: (2020-11-01)